ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
bortezomib reddy 3,5 mg prášok na injekčný roztok
reddy holding gmbh, nemecko - bortezomib - 44 - cytostatica
bortega 3,5 mg
heaton k.s., Česká republika - bortezomib - 44 - cytostatica
bortezomib stada
stada arzneimittel ag, nemecko - bortezomib - 44 - cytostatica
bortezomib medac 3,5 mg
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - bortezomib - 44 - cytostatica
bortezomib sandoz
sandoz pharmaceuticals d.d., slovinsko - bortezomib - 44 - cytostatica
bortezomib mylan 3,5 mg
mylan s.a.s., francúzsko - bortezomib - 44 - cytostatica
bortezomib mylan 1 mg
mylan s.a.s., francúzsko - bortezomib - 44 - cytostatica
bortezomib krka 3,5 mg prášok na injekčný roztok
krka, d.d., novo mesto, slovinsko - bortezomib - 44 - cytostatica
bortezomib krka 1 mg prášok na injekčný roztok
krka, d.d., novo mesto, slovinsko - bortezomib - 44 - cytostatica